Dublin, Sept. 13, 2023 (GLOBE NEWSWIRE) -- The "Exosome Technologies Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.
The global exosome technologies market is poised for remarkable growth, transitioning from $0.04 billion in 2022 to an estimated $0.06 billion in 2023, reflecting an impressive compound annual growth rate (CAGR) of 26.28%. This growth momentum is projected to continue, with the exosome technologies market anticipated to expand to $0.14 billion by 2027, at a CAGR of 26.72%.
The exosome technologies market research report is a valuable addition to a series of comprehensive reports, offering a deep dive into exosome technologies market statistics. It encompasses crucial aspects such as global market size, regional market shares, competitors' presence in the exosome technologies market, segmented insights, emerging market trends, opportunities, and additional pertinent data necessary for thriving within the exosome technologies industry. This comprehensive exosome technologies market research report presents a holistic view, encompassing an exhaustive analysis of the current landscape and future potential of the industry.
Advanced Exosome Characterization Technologies: A Key Trend
A pivotal trend gaining traction within the exosome technology market is the adoption of advanced exosome characterization technologies. Market participants are increasingly integrating cutting-edge technologies to enhance their competitive edge. For instance, Creative Biolabs Inc., a biotech company based in the United States, introduced the NanosightTM platform in August 2022. This platform employs Nanosight technology, leveraging nanoparticle tracking analysis (NTA) techniques for exosome characterization. By visualizing and quantifying exosomes based on size and concentration, this technology aids researchers in comprehending exosome properties and functions, thus driving advanced analysis and research efforts.
Market Expansion Through Acquisition
In November 2021, Lonza, a Swiss biotechnology research company, acquired the exosome manufacturing facility of Codiak BioSciences for $65 million. This strategic acquisition bolsters Lonza's foothold in the exosome market, catering to the growing demand for exosome-based therapeutics and diagnostics. Codiak BioSciences, a U.S.-based biopharmaceutical company, specializes in the development of exosome-based therapeutics.
Market Dynamics by Region
North America secured the position as the largest region in the exosome technologies market in 2022. However, Asia-Pacific is anticipated to exhibit the highest growth rate in the forecast period, signifying a burgeoning market potential in this region. The geographical scope of this report spans Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.
Rising Prevalence of Chronic Diseases as a Growth Driver
The exosome technologies market is set to experience substantial growth due to the increasing prevalence of chronic diseases. The rising incidence of chronic diseases necessitates exosome technologies for various applications such as disease-specific biomarker identification, disease progression monitoring via exosome cargo analysis, targeted drug delivery, and immune modulation in chronic conditions. The aging population contributes to this trend, with projections indicating a surge in the number of individuals aged 50 years and older with chronic illnesses.
Market Composition and Value
The exosome technologies market encompasses revenues earned by entities through services such as vaccine development, biomarker production, exosome-based diagnostic testing, and therapeutic development. The market value encompasses the value of related goods sold alongside the service offering. This includes exosome isolation kits, purification reagents, characterization tools, analysis kits, and exosome-based therapeutic products. The value reflects the creator's "factory gate" values, whether sold to downstream entities or directly to end customers.
In summary, the exosome technologies market is on an upward trajectory, fueled by advanced characterization technologies, strategic acquisitions, and the increasing prevalence of chronic diseases. The market's expansion opportunities are vast, with the potential for significant growth across different regions and industries. With a focus on technological advancements and addressing healthcare needs, the exosome technologies market is poised for transformative growth.
Key Questions Include:
- Where is the largest and fastest-growing market for exosome technologies?
- How does the market relate to the overall economy, demography and other similar markets?
- What forces will shape the market going forward?
Major players in the Exosome Technologies market are
- AEGLE Therapeutics
- Aruna Bio Inc.
- Carmine Therapeutics Inc.
- Exosome Diagnostics Inc.
- Creative Biolabs Inc.
- Danaher Corporation
- OmniSpirant Limited
- Thermo Fisher Scientific Inc.
- Fujifilm Holdings Corporation
- Anjarium Biosciences
- NOVADIP Biosciences S.A.
- Exopharm Ltd.
- Organicell Regenerative
- Evox Therapeutics
- Direct Biologics
- ExoCan Healthcare Technologies Pvt. Ltd.
- ExoCoBio
- ExonanoRNA LLC
- ILIAS Biologics Inc.
- Illumina Inc.
- Invitrix Therapeutics
- XOStem Inc.
- VivaZome Therapeutics Pty Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/tsu79
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
